Literature DB >> 26911562

Identification of potential Gly/NMDA receptor antagonists by cheminformatics approach: a combination of pharmacophore modelling, virtual screening and molecular docking studies.

V G Ugale1, S B Bari2.   

Abstract

The Gly/NMDA receptor has become known as potential target for the management of neurodegenerative diseases. Discovery of Gly/NMDA antagonists has thus attracted much attention in recent years. In the present research, a cheminformatics approach has been used to determine structural requirements for Gly/NMDA antagonism and to identify potential antagonists. Here, 37 quinoxaline derivatives were selected to develop a significant pharmacophore model with good certainty. The selected model was validated by leave-one-out cross-validation, an external test set, decoy set and Y-randomization test. Applicability domain was verified by the standardization approach. The validated 3D-QSAR model was used to screen virtual hits from the ZINC database by pharmacophore mapping. Molecular docking was used for assessment of receptor-ligand binding modes and binding affinities. The GlideScore and molecular interactions with critical amino acids were considered as crucial features to identify final hits. Furthermore, hits were analysed for in silico pharmacokinetic parameters and Lipinski's rule of five, demonstrating their potential as drug-like candidates. The PubChem and SciFinder search tools were used to authenticate the novelty of leads retrieved. Finally, five different leads have been suggested as putative novel candidates for the exploration of potent Gly/NMDA receptor antagonists.

Entities:  

Keywords:  3D-QSAR; Gly/NMDA receptor; molecular docking; pharmacophore mapping; virtual screening

Mesh:

Substances:

Year:  2016        PMID: 26911562     DOI: 10.1080/1062936X.2015.1136679

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  5 in total

1.  Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents.

Authors:  Visarapu Malathi; Nissi Sharon; Pannala Padmaja; Deepak Lokwani; Saurabh Khadse; Prashant Chaudhari; Atul A Shirkhedkar; Pedavenkatagari Narayana Reddy; Vinod G Ugale
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

2.  Computational identification of 2,4-disubstituted amino-pyrimidines as L858R/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulation.

Authors:  Rahul Pawara; Iqrar Ahmad; Sanjay Surana; Harun Patel
Journal:  In Silico Pharmacol       Date:  2021-10-06

Review 3.  Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands.

Authors:  Laura Blaikie; Graeme Kay; Paul Kong Thoo Lin
Journal:  Medchemcomm       Date:  2019-10-16       Impact factor: 3.597

4.  Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining.

Authors:  Samer Haidar; Zouhair Bouaziz; Christelle Marminon; Tuomo Laitinen; Antti Poso; Marc Le Borgne; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-09

5.  Xylazine Regulates the Release of Glycine and Aspartic Acid in Rat Brain.

Authors:  Yi-Ming Zhang; Dong-Xu Yu; Bai-Shuang Yin; Xin-Ran Li; Li-Na Li; Ya-Nan Li; Yu-Xin Wang; Yu Chen; Wen-Han Liu; Li Gao
Journal:  J Vet Res       Date:  2018-03-30       Impact factor: 1.744

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.